milbemycin oxime 5.75 mg Tablet, 55,000-count — NDC 58198-4860-1 (Billing 58198-4860-01)
This is a package of 55,000 tablets of milbemycin oxime 5.75 mg Tablet from Elanco US Inc., marketed since Jul 1994 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 58198-4860-1 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 58198 labeler · 4860 product · 1 package
- Package marketed since
- Jul 21, 1994
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 5819848601 5
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
Clinical
This is a tablet containing milbemycin oxime, an antiparasitic medication typically used in veterinary medicine to treat or prevent parasitic infections in animals, particularly heartworm and certain intestinal worms. The tablet form is marked as a drug for further processing, meaning this listing represents bulk or intermediate product rather than a finished consumer medication. Milbemycin oxime works by interfering with the nervous system of susceptible parasites.
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 5, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 58198-4860-01 You're viewing this Main listing | 1 BAG in 1 DRUM / 55000 TABLET in 1 BAG | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| milbemycin oxime 5.75 mgthis 58198-4860-01 | Elanco | 55000 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 5, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Elanco US Inc. labeler code 58198
- lotilaner 450 mg Tablet, Chewable NDC 58198-4541-1
- lotilaner 225 mg Tablet, Chewable NDC 58198-4561-1
- lotilaner 112.5 mg Tablet, Chewable NDC 58198-4581-1
- Butafosfan and Cyanocobalamin 100 mg/mL; .05 mg/mL Injection NDC 58198-4682-1
- milbemycin oxime 23 mg Tablet NDC 58198-4850-1
- milbemycin oxime 11.5 mg Tablet NDC 58198-4855-1
- milbemycin oxime 2.3 mg Tablet NDC 58198-4865-1
- lotilaner 12 mg Tablet, Chewable NDC 58198-4872-1
- lotilaner 48 mg Tablet, Chewable NDC 58198-4881-1
- ilunocitinib 4.8 mg Tablet NDC 58198-5361-1
- ilunocitinib 6.4 mg Tablet NDC 58198-5371-1
- ilunocitinib 8.5 mg Tablet NDC 58198-5381-1
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Elanco US Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |